2025年第36届CINP世界神经精神药理学大会

◆ 会议时间：2025年6月15-18日
◆ 会议地点：澳大利亚-墨尔本

◆ 会议简介：

2025年第36届世界神经精神药理学大会-国际神经精神药理学会(CINP)世界大会将于2025年6月15日至18日在澳大利亚墨尔本举行。

国际神经精神药理学会（CINP）成立于1957年，是一个得到全世界广泛支持的全球性精神药理学组织，其成员包括精神科医师、药理学家和基础科学家以及研究心理学家等。CINP的使命是鼓励和促进国际科学研究、教学和神经精神药理学的应用，为神经精神药物各个方面的评价宣提供建议和咨询，包括生物化学，药理学、安全性和治疗功效等，通过这些举措，CINP力求改进和推进研究活动，尽而改善患者的护理（未经许可禁止复制摘录转载本站任何内容-国际医学会议网(lingyuint.com)。

CINP-AsCNP 2025
36th World Congress of Neuropharmacology
International College of Neuropsychopharmacology (CINP) World Congress

Date:
June 15-18, 2025

Venue:
Melbourne Convention and Exhibition Centre
Melbourne, Australia

摘要征文投稿：

May 23, 2024
Symposia Submission OPEN

September 30, 2024 at 23:59 CEST
Symposia Submission CLOSED

by November 15, 2024
Symposia Acceptance Notification

August 30, 2024
Abstract Submission OPEN – 摘要征文投稿开始

December 16, 2024
Abstract Submission CLOSED

February 7, 2025
Abstract Acceptance Notification

February 14, 2025 at 23:59 CET
Congress Registration Deadline for Abstract Submitters:

点此提交摘要>>>Submit Abstract>>>

PRESENTATION TYPES

Data Blitz (Oral Presentation 6 min)
Featured Communication (Oral Presentation 15 min)
Poster displayed in the Exhibition Area

Please note that oral presenters are asked to bring a poster as well.

SUBMISSION GUIDELINES

There is no fee for submitting a an abstract.
Abstracts will be accepted in English only.
As a presenting author, you can submit a maximum number of 2 abstracts.
Abstracts must be a maximum of 500 words.
A table or picture will count as 150 words. Maximum upload: 1 table and 1 picture.
The picture must have an alt text (text to describe what’s in the picture).
The total word count includes tables, pictures and alt text. It does, however, not include the title, authors’ details or references.
The presenting author is responsible of passing on information to co-authours.
CINP recommends using the NbN nomenclature for psychotropics (http://nbn2r.com)
CINP-AsCNP 2025 Abstracts will be reviewed and selected by the International Scientific Programme Committee.
Presenting authors must register & pay for the CINP-AsCNP 2025 Joint Congress by February 14.

Abstract submission is structured as follows:

Background
Aims & Objectives
Method
Results
Discussion & Conclusion

AWARD APPLICATION

If you match the application criteria, during the abstract submission process you will be offered the possibility to apply for the following awards:
Rafaelsen Young Investigators Award: open September 30 – November 15
Student Encouragement Award: open September 30 – December 16

Topic 1 Research

Clinical
Preclinical
Translational
Other

Topic 2 Disorder

Addiction Disorders
Anxiety Disorders
Attention Deficit Disorders
Autism
Bipolar Disorders
Childhood & Adolescent Disorders
COVID-19
Dementia
Depression
Eating Disorders
Epilepsy
Obsessive-Compulsive Disorders
Pain
Panic Disorders
Personality Disorders
Post-Traumatic Stress Disorders
Premenstrual Dysphoric Disorder
Schizophrenia
Sexual Disorders
Sleep Disorders
Suicide
Other

Topic 3 Drug Methodology

Animal Models
Anxiolytics
Brain Stimulation
Computational Neuroscience
Drugs for Bipolar Disorders
Drugs for Depression
Drugs for Insomnia
Drugs for Psychosis
Ethics of Psychopharmacology
Genetics
History of Psychopharmacology
Imaging
Molecular Neurobiology/Pharmacology
Neuropathology/Post-Mortem Studies
Neurophysiology
Oriental Medicine
Pharmacoeconomics
Pharmacogenetics/Kinetics
Psychoneuroimmunology
Transcultural Psychopharmacology
Other

Welcome to Melbourne!

We look forward to welcoming you to the World Congress of Neuropsychopharmacology as it returns to Australia for the first time in nearly 30 years. CINP-AsCNP 2025, the 36TH World Congress, will be held at the Melbourne Convention and Exhibition Centre from Sunday, June 15TH to Wednesday, June 18TH, 2025, around the theme ‘Advancing Intelligent Horizons Towards Brain Health’. We plan to increase the opportunity for delegate interaction by incorporating a variety of new session formats and hope to combine scientific content of the highest quality with extensive networking opportunities and a memorable social and cultural experience.

With the development of science and technology in recent years, efforts to apply neuropsychopharmacology to clinical practice in neuropsychiatric disorders have flourished worldwide. There have been many important developments within Australia, which has developed a youth mental health paradigm and clinical staging for early psychosis including at risk states. Moreover, Australia is the first country to permit the use of psilocybin assisted therapy for treatment resistant depression and MDMA assisted therapy for post-traumatic stress disorder (July 2023) and has also pioneered trials in psilocybin assisted therapy for generalised anxiety disorder.